Skinhealth Systems Inc Financials
Skinhealth Systems Inc (SKIN) reported $300.8M in revenue for fiscal year 2025, down 10.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Margin repair and working-capital release are turning a shrinking revenue base into real cash, even as the liquidity cushion thins.
From FY2023 to FY2025, gross margin rebounded from39.0% to65.3% , and that repair coincided with operating cash flow staying positive even while earnings remained below breakeven. Because capex was only$303K in FY2025, almost every operating dollar became free cash flow, so the recent cash generation looks more like a lighter operating model than an accounting artifact.
The business is no longer burning cash the way it did in FY2022, but its balance-sheet cushion is much smaller: cash fell from
Liabilities of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Skinhealth Systems Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Skinhealth Systems Inc has an operating margin of -6.9%, meaning the company loses $7 on every $100 of revenue. This results in a profitability score of 27/100. This is up from -20.3% the prior year.
Skinhealth Systems Inc's revenue declined 10.0% year-over-year, from $334.3M to $300.8M. This contraction results in a growth score of 8/100.
Skinhealth Systems Inc has elevated debt relative to equity (D/E of 7.19), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 7/100, reflecting increased financial risk.
Skinhealth Systems Inc's current ratio of 1.66 indicates adequate short-term liquidity, earning a score of 47/100. The company can meet its near-term obligations, though with limited headroom.
Skinhealth Systems Inc has a free cash flow margin of 12.4%, earning a moderate score of 63/100. The company generates positive cash flow after capital investments, but with room for improvement.
Skinhealth Systems Inc posts a -15.6% return on equity (ROE), meaning it loses $16 for every $100 of shareholders' equity. This results in a returns score of 29/100. This is up from -56.2% the prior year.
Skinhealth Systems Inc scores -0.58, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($78.1M) relative to total liabilities ($438.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Skinhealth Systems Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Skinhealth Systems Inc reported a net loss of $9.5M while generating $37.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Skinhealth Systems Inc reported an operating loss of $20.8M against $19.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Skinhealth Systems Inc generated $300.8M in revenue in fiscal year 2025. This represents a decrease of 10.0% from the prior year.
Skinhealth Systems Inc's EBITDA was $33K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.1% from the prior year.
Skinhealth Systems Inc reported -$9.5M in net income in fiscal year 2025. This represents an increase of 67.4% from the prior year.
Skinhealth Systems Inc earned -$0.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 55.6% from the prior year.
Cash & Balance Sheet
Skinhealth Systems Inc generated $37.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 141.8% from the prior year.
Skinhealth Systems Inc held $232.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Skinhealth Systems Inc's gross margin was 65.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 10.8 percentage points from the prior year.
Skinhealth Systems Inc's operating margin was -6.9% in fiscal year 2025, reflecting core business profitability. This is up 13.4 percentage points from the prior year.
Skinhealth Systems Inc's net profit margin was -3.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 5.5 percentage points from the prior year.
Skinhealth Systems Inc's ROE was -15.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 40.6 percentage points from the prior year.
Capital Allocation
Skinhealth Systems Inc invested $5.6M in research and development in fiscal year 2025. This represents a decrease of 10.6% from the prior year.
Skinhealth Systems Inc repurchased no shares in fiscal year 2025.
Skinhealth Systems Inc invested $303K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 59.9% from the prior year.
SKIN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $290.0M | $300.8M-10.0% | $334.3M-16.0% | $398.0M+8.8% | $365.9M+40.7% | $260.1M+118.4% | $119.1M-28.5% | $166.6M |
| Cost of Revenue | $97.6M | $104.4M-31.3% | $152.0M-37.4% | $242.9M+107.4% | $117.1M+43.6% | $81.5M+57.1% | $51.9M-13.7% | $60.1M |
| Gross Profit | $192.4M | $196.4M+7.7% | $182.3M+17.5% | $155.1M-37.7% | $248.8M+39.3% | $178.5M+165.7% | $67.2M-36.9% | $106.5M |
| R&D Expenses | $5.9M | $5.6M-10.6% | $6.3M-37.7% | $10.1M+19.6% | $8.4M+3.0% | $8.2M+140.4% | $3.4M-26.1% | $4.6M |
| SG&A Expenses | $102.2M | $117.9M-6.0% | $125.5M-4.5% | $131.4M+23.9% | $106.1M+7.5% | $98.7M+222.0% | $30.6M+15.0% | $26.7M |
| Operating Income | -$4.3M | -$20.8M+69.3% | -$67.8M+48.2% | -$130.9M-406.6% | -$25.8M+35.3% | -$39.9M-132.4% | -$17.2M-227.6% | $13.5M |
| Interest Expense | $25.3M | $19.3M+85.6% | $10.4M-23.7% | $13.6M+1.9% | $13.4M+13.7% | $11.8M | N/A | N/A |
| Income Tax | $4.7M | $3.6M+892.3% | -$452K+74.5% | -$1.8M-259.0% | $1.1M+159.5% | -$1.9M+79.9% | -$9.3M-617.7% | -$1.3M |
| Net Income | -$28.4M | -$9.5M+67.4% | -$29.1M+70.9% | -$100.1M-326.5% | $44.2M-88.3% | $378.7M+1398.0% | -$29.2M-1681.1% | -$1.6M |
| EPS (Diluted) | — | -$0.16+55.6% | -$0.36 | -$0.76-230.4% | -$0.23+93.8% | -$3.71 | -$0.85-1600.0% | -$0.05 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SKIN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $499.8M-27.1% | $685.7M-26.2% | $929.1M-7.4% | $1.0B-17.7% | $1.2B+447.0% | $222.8M | N/A |
| Current Assets | $309.5M-35.1% | $477.1M-31.7% | $698.3M-10.9% | $783.3M-21.7% | $1.0B+1593.7% | $59.1M | N/A |
| Cash & Equivalents | $232.7M-37.1% | $370.1M-29.2% | $523.0M-8.0% | $568.2M-37.0% | $901.9M+9407.5% | $9.5M+29.8% | $7.3M |
| Inventory | $48.0M-30.5% | $69.1M-24.3% | $91.3M-16.7% | $109.7M+211.0% | $35.3M+52.0% | $23.2M | N/A |
| Accounts Receivable | $21.7M-21.4% | $27.6M-49.5% | $54.7M-28.5% | $76.5M+63.4% | $46.8M+152.1% | $18.6M | N/A |
| Goodwill | $126.6M+2.5% | $123.5M-1.8% | $125.8M+1.0% | $124.6M+0.7% | $123.7M+25.5% | $98.5M0.0% | $98.5M |
| Total Liabilities | $438.7M-30.8% | $633.9M-27.1% | $869.7M+4.0% | $836.0M-8.8% | $916.5M+262.6% | $252.8M | N/A |
| Current Liabilities | $186.3M+173.3% | $68.2M-40.7% | $115.0M+60.4% | $71.7M-6.2% | $76.4M+147.1% | $30.9M | N/A |
| Long-Term Debt | N/A | $552.2M | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $61.1M+17.9% | $51.8M-12.8% | $59.4M-64.4% | $167.1M-43.9% | $298.0M+1075.0% | -$30.6M-2430.4% | -$1.2M |
| Retained Earnings | -$517.5M-1.9% | -$508.0M-6.1% | -$478.9M-26.4% | -$378.8M+9.5% | -$418.7M-860.3% | -$43.6M | N/A |
SKIN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $22.0M | $37.5M+132.3% | $16.1M-25.8% | $21.8M+120.4% | -$106.6M-275.9% | -$28.4M-128.1% | -$12.4M-819.7% | $1.7M |
| Capital Expenditures | $817K | $303K-59.9% | $756K-80.2% | $3.8M-64.7% | $10.8M-3.2% | $11.2M+219.9% | $3.5M-60.1% | $8.8M |
| Free Cash Flow | $21.1M | $37.2M+141.8% | $15.4M-14.2% | $17.9M+115.3% | -$117.4M-196.9% | -$39.6M-148.2% | -$15.9M-126.2% | -$7.0M |
| Investing Cash Flow | -$5.3M | -$5.2M+24.0% | -$6.8M+78.4% | -$31.5M-67.0% | -$18.9M+50.0% | -$37.7M-888.5% | -$3.8M+69.4% | -$12.5M |
| Financing Cash Flow | -$22.4M | -$174.9M-10.5% | -$158.3M-322.8% | -$37.4M+81.8% | -$205.2M-121.4% | $959.0M+5148.4% | $18.3M+25.3% | $14.6M |
| Share Buybacks | N/A | $0 | $0-100.0% | $30.2M-81.2% | $160.0M | $0-100.0% | $154K | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SKIN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 65.3%+10.8pp | 54.5%+15.6pp | 39.0%-29.0pp | 68.0%-0.6pp | 68.7%+12.2pp | 56.4%-7.5pp | 63.9% |
| Operating Margin | -6.9%+13.4pp | -20.3%+12.6pp | -32.9%-25.8pp | -7.1%+8.3pp | -15.3%-0.9pp | -14.4%-22.5pp | 8.1% |
| Net Margin | -3.2%+5.5pp | -8.7%+16.4pp | -25.1%-37.2pp | 12.1% | 145.6% | -24.5%-23.5pp | -1.0% |
| Return on Equity | -15.6%+40.6pp | -56.2%+112.4pp | -168.6%-195.0pp | 26.5%-100.6pp | 127.1% | N/A | N/A |
| Return on Assets | -1.9%+2.3pp | -4.2%+6.5pp | -10.8%-15.2pp | 4.4%-26.7pp | 31.1%+44.2pp | -13.1% | N/A |
| Current Ratio | 1.66-5.3x | 7.00+0.9x | 6.07-4.9x | 10.92-2.2x | 13.09+11.2x | 1.91 | N/A |
| Debt-to-Equity | 7.19-3.5x | 10.66-4.0x | 14.64+9.6x | 5.00+1.9x | 3.08 | N/A | N/A |
| FCF Margin | 12.4%+7.8pp | 4.6%+0.1pp | 4.5%+36.6pp | -32.1%-16.9pp | -15.2%-1.8pp | -13.4%-9.2pp | -4.2% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Where Skinhealth Systems Inc Ranks
Frequently Asked Questions
What is Skinhealth Systems Inc's annual revenue?
Skinhealth Systems Inc (SKIN) reported $300.8M in total revenue for fiscal year 2025. This represents a -10.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Skinhealth Systems Inc's revenue growing?
Skinhealth Systems Inc (SKIN) revenue declined by 10.0% year-over-year, from $334.3M to $300.8M in fiscal year 2025.
Is Skinhealth Systems Inc profitable?
No, Skinhealth Systems Inc (SKIN) reported a net income of -$9.5M in fiscal year 2025, with a net profit margin of -3.2%.
What is Skinhealth Systems Inc's EBITDA?
Skinhealth Systems Inc (SKIN) had EBITDA of $33K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Skinhealth Systems Inc's gross margin?
Skinhealth Systems Inc (SKIN) had a gross margin of 65.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Skinhealth Systems Inc's operating margin?
Skinhealth Systems Inc (SKIN) had an operating margin of -6.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Skinhealth Systems Inc's net profit margin?
Skinhealth Systems Inc (SKIN) had a net profit margin of -3.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Skinhealth Systems Inc's return on equity (ROE)?
Skinhealth Systems Inc (SKIN) has a return on equity of -15.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Skinhealth Systems Inc's free cash flow?
Skinhealth Systems Inc (SKIN) generated $37.2M in free cash flow during fiscal year 2025. This represents a 141.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Skinhealth Systems Inc's operating cash flow?
Skinhealth Systems Inc (SKIN) generated $37.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Skinhealth Systems Inc's total assets?
Skinhealth Systems Inc (SKIN) had $499.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Skinhealth Systems Inc's capital expenditures?
Skinhealth Systems Inc (SKIN) invested $303K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Skinhealth Systems Inc spend on research and development?
Skinhealth Systems Inc (SKIN) invested $5.6M in research and development during fiscal year 2025.
What is Skinhealth Systems Inc's current ratio?
Skinhealth Systems Inc (SKIN) had a current ratio of 1.66 as of fiscal year 2025, which is generally considered healthy.
What is Skinhealth Systems Inc's debt-to-equity ratio?
Skinhealth Systems Inc (SKIN) had a debt-to-equity ratio of 7.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Skinhealth Systems Inc's return on assets (ROA)?
Skinhealth Systems Inc (SKIN) had a return on assets of -1.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Skinhealth Systems Inc's Altman Z-Score?
Skinhealth Systems Inc (SKIN) has an Altman Z-Score of -0.58, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Skinhealth Systems Inc's Piotroski F-Score?
Skinhealth Systems Inc (SKIN) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Skinhealth Systems Inc's earnings high quality?
Skinhealth Systems Inc (SKIN) reported a net loss of $9.5M while generating $37.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Skinhealth Systems Inc cover its interest payments?
Skinhealth Systems Inc (SKIN) reported an operating loss of $20.8M against $19.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Skinhealth Systems Inc?
Skinhealth Systems Inc (SKIN) scores 30 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.